Small Round Cell SarcomasDisclosures
Small round cell sarcomas are the most aggressive of the tumors morphologically and clinically encountered in children and adults, and in some ways the most leukemia- or lymphoma-like of sarcomas. Small round cell sarcomas often are associated with chromosomal translocations, like hematologic malignancies, and are usually more sensitive to chemotherapy than other sarcoma subtypes. They have a high risk of mortality, but chemotherapy (in addition to surgery and often radiation therapy) provides a good cure rate, although treatment is often long and intensive. The biology of these tumors is very telling in terms of some of the mechanisms of cancer cell survival and proliferation. Although there is some overlap of the discussion below with the section on translocation associated sarcomas, we have highlighted some of the key issues with these sarcomas below, with some ideas that may bear fruit both in terms of the management of these, other sarcomas, and other cancers alike.
To access this article, please choose from the options below
Stephen L. Lessnick is supported by the Terri Anna Perine Sarcoma Fund, the Liddy Shriver Sarcoma Initiative, American Cancer Society Research Scholar Grant No. MGO-111812, and a Huntsman Cancer Institute Director's Translational Research Initiative Grant. S.L.L. also acknowledges NIH support to Huntsman Cancer Institute via P30 CA042014. Poul H.B. Sorensen is supported by grants from the Canadian Institutes of Health Research (CIHR).
Disclosures Stephen L. Lessnick: Owns stock in Merck, Inc, the makers of vorinostat. Merck provided the vorinostat used in Dr Lessnick's studies.Laurence H. Baker: Hoffman-La Roche supports clinical trials and research by the Sarcoma Alliance for Research through Collaboration, on whose executive board Dr Baker is a member.
PII: S0093-7754(09)00106-7
doi:10.1053/j.seminoncol.2009.06.006
© 2009 Published by Elsevier Inc.
